As modulating BCAA metabolism, a downstream component of the GC-GR-Klf15 signalling cascade, provided significant improvements in SMA mice, it is possible that targeting an upstream effector may lead to a more direct and specific modulation of the GC-Klf15 pathway and thus, greater benefits. The gene discussed is NR3C1; the disease is proximal spinal muscular atrophy.